Mubadala Investment Co PJSC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Mubadala Investment Co PJSC purchased a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 144,400 shares of the biopharmaceutical company's stock, valued at approximately $3,831,000. Pfizer comprises about 0.0% of Mubadala Investment Co PJSC's portfolio, making the stock its 22nd biggest position.

A number of other large investors have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Pfizer by 8.2% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,090,774 shares of the biopharmaceutical company's stock worth $28,934,000 after acquiring an additional 82,594 shares during the last quarter. Leigh Baldwin & CO. LLC acquired a new position in Pfizer during the 4th quarter worth approximately $45,383,000. Letko Brosseau & Associates Inc. boosted its position in Pfizer by 29.2% during the 4th quarter. Letko Brosseau & Associates Inc. now owns 3,863,988 shares of the biopharmaceutical company's stock worth $102,512,000 after acquiring an additional 872,530 shares during the last quarter. Lighthouse Investment Partners LLC acquired a new position in Pfizer during the 4th quarter worth approximately $2,809,000. Finally, Lionshead Wealth Management LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $716,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Trading Up 3.6%

Shares of Pfizer stock opened at $23.09 on Tuesday. The business has a fifty day simple moving average of $23.96 and a two-hundred day simple moving average of $25.48. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a market capitalization of $131.25 billion, a price-to-earnings ratio of 16.37, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.82 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.45%. The ex-dividend date is Friday, May 9th. Pfizer's payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on PFE shares. UBS Group increased their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. Finally, Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Pfizer has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.